ARRS Opportunities and Obligations in Imaging Patients with Alzheimer’s Disease 2025

Date of Original Release: Aug 2025

Anti-amyloid targeting disease-modifying therapies for Alzheimer’s disease present an exciting opportunity to dramatically impact the lives of patients with Alzheimer’s dementia. The imaging impact is already formidable, with a significant rise in MRI volume. Amyloid PET volumes have also skyrocketed following a positive reimbursement decision for patient selection and treatment surveillance.

Learning Outcomes and Modules

• Identify the challenges and opportunities of AD in the era of DMT.
• Discuss the benefits and risks of amyloid targeting therapies.
• Discuss clinical implications of ARIA grading and multidisciplinary communication.
• Recognize the role of molecular imaging in the dementia imaging pathway.

Speakers and Lectures

• Multimodal Dementia Imaging with Emphasis on Alzheimer’s Disease and ARIA Cases—Suzie Bash
• Enterprise Workflow Optimization for Alzheimer’s Screening and ARIA Surveillance—Lawrence Tanenbaum
• Radiology Perspective: Multidisciplinary Approach to Challenging Cases—Tammie Benzinger